Burnaby, Canada

Monan Angela Zhang

USPTO Granted Patents = 1 

Average Co-Inventor Count = 10.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2022

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Monan Angela Zhang: Innovator in Immune Response Therapeutics

Introduction

Monan Angela Zhang is a prominent inventor based in Burnaby, Canada. She has made significant contributions to the field of immunology through her innovative research and patent work. Her dedication to advancing therapeutic strategies has positioned her as a key figure in her area of expertise.

Latest Patents

Monan Angela Zhang holds a patent for her invention titled "Therapeutically triggering an innate immune response in a target tissue." This invention provides therapeutic compositions that present an artificial repertoire of mammalian pattern recognition receptor (PRR) agonists. The goal is to recapitulate a distinct portion of a PRR agonist signature of a mammalian pathogen. The artificial repertoire of PRR agonists can be formulated together in a therapeutic vehicle for combined presentation to an innate immune cell resident in a target tissue in a mammalian host. This vehicle is adapted to deliver the PRR agonists to the target tissue, thereby modulating an immune response.

Career Highlights

Monan Angela Zhang is associated with Qu Biologics Inc., where she continues to develop her innovative ideas and contribute to the field of immunotherapy. Her work is characterized by a commitment to enhancing therapeutic options for patients through scientific research and development.

Collaborations

Some of her notable coworkers include Harold David Gunn and David W Mullins, who collaborate with her on various projects within the company.

Conclusion

Monan Angela Zhang's contributions to the field of immunology through her patent and work at Qu Biologics Inc. highlight her role as an influential inventor. Her innovative approach to therapeutic compositions demonstrates the potential for advancing immune response treatments.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…